Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab-Pfizer Biosimilar Post-Marketing Database Study

NCT05796245 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05796245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05796245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab-Pfizer Biosimilar Post-Marketing Database Study
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
December 1, 2023
Completion date
March 14, 2024
Enrollment
2,207 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, colitis, ulcerative, crohn disease, psoriasis